NGC Update Service: May 2, 2016

National Guideline Clearinghouse (NGC)

May 2, 2016

New This Week

Guideline Synthesis

Guideline Summaries

National Blood Authority New Developer

Withdrawn Summaries

The summaries listed below have been withdrawn from the NGC Web site because they no longer meet the NGC Inclusion Criteria. See the Guideline Archive for a complete list of guidelines that have been withdrawn from the NGC Web site.

American College of Obstetricians and Gynecologists

  • Invasive prenatal testing for aneuploidy.
  • Screening for fetal chromosomal abnormalities.

Institute for Clinical Systems Improvement

  • Healthy lifestyles.

World Health Organization

  • Guidelines for the screening, care and treatment of persons with hepatitis C infection.

Announcements

Conference News

  • The Guidelines International Network (G-I-N) 13th annual conference will take place from September 27-30, 2016 in Philadelphia. This conference will be co-hosted by the American College of Physicians, ECRI Institute and Penn Medicine. The theme is "Individualised Guidelines and Clinical Performance Measurement in an Era of Personalised Medicine." Registration now open. For more information, visit the G-I-N Conference Web site.
  • The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, are available on the G-I-N Web site.

U.S. Food and Drug Administration (FDA) Advisory

  • April 26, 2016: Fluconazole (Diflucan): FDA is evaluating the results of a Danish study that conclude there is a possible increased risk of miscarriage with the use of oral fluconazole (Diflucan) for yeast infections. FDA is also reviewing additional data and will communicate final conclusions and recommendations when the review is complete.

    The current FDA drug label states that data available from studies in people do not suggest an increased risk of problems during pregnancy or abnormalities in developing babies when women are exposed to a single 150 mg dose of oral fluconazole to treat vaginal yeast infections. However, high doses of oral fluconazole (400-800 mg/day) taken by pregnant women for much longer than a single dose have resulted in reports of abnormalities at birth. In the Danish study, most of the oral fluconazole use appeared to be one or two doses of 150 mg.

Health Awareness Topics - May 2016

How to Participate

  • Submit Guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.
  • Suggest a Guideline for Possible Inclusion: Submit your suggestions for evidence-based clinical practice guidelines that you would like to see included in NGC.

NGC's Sister Resource